January #98 : Chicago Hope? - by Tim Murphy

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

10 Ways to End AIDS (in 10 years)

Happy New You

Political Science

"Prevention" for Positives

Habitats for HIVers

On the Job

Going Under Cover

All the Right Places

2024: AIDS Cured, ex-PWAs Ignored

Trouble Indemnity

Earthwatch

Show & Gel

Healthful Humor

Living on Hope

Milestones

High Resolution: New Year’s Creeds

2004: What’s In, What’s Out?

Briefs

When Your CD4s Count

New Med on the Shelf

Quick Study: Virus in Vaginas

Strike a Pose

Chicago Hope?

Quick Study: Hep C

Watch Your Mouth

2X

CMV Drug Does Double Duty

Bed Head

Unreality TV

Mailbox

Publisher's Letter

Amazing Race



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

January 2004

Chicago Hope?

by Tim Murphy

A snoozy HIV summit’s greatest hits

The all-that-jazz city simmered down last September for—deep breath—the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), the annual big-deal revue where researchers trot out new HIV data. This year’s crop? “Thin,” says Cincinnati HIV doc Judith Feinberg, MD. The few show-stoppers:

KALETRA KUDOS ICAAC’s shocker was a scrappy but small study by Houston’s Joe Gathe, MD, who started 30 patients (with an average CD4 count of 169 and viral load of 250,000) on the PI Kaletra (ritonavir/lopinavir) alone—that’s right: no nukes! Of the 22 who stayed in the trial after six months, all but one reached undetectable—and an average CD4 count over 200. Is this the dawn of a simpler, cheaper, less side-effect-ridden starting option that actually works? “I’m a believer,” says Florida’s Gerald Pierone, MD.

NO NUKES-ONLY The triple-nuke combo Ziagen (abacavir), Epivir (3TC) and Viread (tenofovir) bombed as a starter regimen compared to Ziagen, 3TC plus non-nuke Sustiva (efavirenz). After the flop of triple-nuke only Trizivir against nukes-plus-Sustiva for newbies, this latest casts even more doubt on starting HAART with nukes alone. Feinberg says her patients have been on triple-nuke combos in studies, but “I’d rarely prescribed it and I’m even less inclined to now.”

LINER NOTES A study found that when HIVers got therapeutic drug monitoring (TDM)—the lab test that measures the actual levels of a drug in your system—and then had med doses adjusted based on the TDM reading, they ended up with fewer side effects but just as good HIV management as a group without TDM. On the treatment horizon, Pfizer’s experimental oral entry inhibitor, UK-427,857, squashed viral loads in HIVers for 10 days with no major side effects.




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    andais
    Red House
    West Virginia


    Newhopenate
    New Hope
    Pennsylvania


    OahuAJ
    Turlock
    California


    daino1972
    Columbus
    Ohio
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.